Given the recent increase in attention to the topic of clinical research in the wake of the COVID-19 pandemic, CISCRP conducted a brief survey to assess what impact the pandemic has had on levels of understanding, perceptions, and experiences related to clinical research. This report outlines key findings from this survey.

Where appropriate, CISCRP draws comparisons between this brief survey and the 2019 Perceptions and Insights Study (a large-scale global survey on public and patient perceptions of clinical research).

The Center for Information and Study on Clinical Research Participation (CISCRP), founded in 2003, is a non-profit organization dedicated to educating the public and patients about the important role that clinical research plays in advancing public health. As part of its mission, CISCRP provides a variety of services designed to assist clinical research stakeholders in (1) understanding public and patient attitudes and experiences and (2) improving volunteer participation experiences and satisfaction. Please consider making a charitable donation to support our mission.
## Methods & Survey Sample

CISCRP fielded an online global survey on April 9th, 2020

### SAMPLE SIZE
- 500 individuals completed the survey

### COUNTRIES
- United States (47%)
- United Kingdom (13%)
- France (13%)
- Germany (13%)
- Italy (13%)

### Gender
- 55% Female
- 43% Male
- 1% All other genders

### Age
- 39% 34 years & under
- 21% 35-44 years
- 17% 45-54
- 13% 55-64 years
- 11% 65 years or older

### Race
- 85% White
- 6% Black
- 6% Asian
- 3% Other

### Ethnicity
- 89% Non-Hispanic
- 11% Hispanic

### Clinical Trial Experience
- 18% Participated
- 82% Never Participated

*Of those who have participated, more than half (56%) are currently enrolled in a clinical trial for COVID-19.*

### COVID-19
- 12% Experienced symptoms
- 9% Tested

Note: Percentages throughout this report may not total 100 due to rounding
Awareness of COVID-19 Trials

Overall, most have not heard of specific clinical research studies for COVID-19 (58%)*.

Those who heard about a clinical trial most commonly heard about the study from traditional ads, such as on TV, radio newspaper or ads on public transportation (27%).

**BY REGION**

More Europeans (40%) than North Americans (34%) have heard of a COVID-19 clinical research study in recruitment.

**BY TRIAL EXPERIENCE**

Those with clinical trial experience are significantly more aware of COVID-19 clinical research studies in recruitment (62%) compared to those who have never participated (31%).

**BY COVID-19 SYMPTOMS, TESTING**

Those who have experienced COVID-19 symptoms are also significantly more aware (58%) of clinical research studies for the virus compared to those who have not experienced symptoms (34%).

Those who have been tested for COVID-19 are also significantly more aware (62%) compared to those who have not been tested (34%).

---

* n=438 | Base: All respondents, excludes “Don’t remember”
Perceptions of Trust and Safety

Similar to the baseline 2019 Perceptions & Insights Study, the COVID-19 survey finds that the majority (78%) consider clinical research to be ‘somewhat’ or ‘very’ safe.

SAFETY CONCERNS

About half (49%) of those who think clinical trials are ‘not very’ or ‘not at all safe’ most commonly mention fears of side effects.

‘Why do you think clinical trials aren’t safe?’

1. There may be side effects (49%)
2. Symptoms could get worse (29%)
3. I don’t know enough about research (25%)
4. I don’t trust pharmaceutical companies (23%)
5. Too many invasive procedures involved (20%)

LEVELS OF TRUST

Overall, trust in pharmaceutical companies ranks lower than other research stakeholders.

How much do you trust the following organizations?

- Pharmaceutical companies
- Government research organizations (NIH, CDC)
- Research centers, clinics
- Regulatory authorities (FDA, EMA)

<table>
<thead>
<tr>
<th>Organization</th>
<th>A lot</th>
<th>Some</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical companies</td>
<td>47%</td>
<td>17%</td>
</tr>
<tr>
<td>Government research organizations</td>
<td>45%</td>
<td>27%</td>
</tr>
<tr>
<td>Research centers, clinics</td>
<td>49%</td>
<td>29%</td>
</tr>
<tr>
<td>Regulatory authorities (FDA, EMA)</td>
<td>50%</td>
<td>24%</td>
</tr>
</tbody>
</table>

Base: All respondents
Most understand clinical research ‘somewhat’ or ‘very’ well (89%) – a finding consistent with the baseline 2019 Perceptions & Insights Study.

However, many have unrealistic expectations as to when a new treatment and/or vaccine for COVID-19 will be developed and made available. More than half (60%) believe a treatment or vaccine will be developed in under a year. Once developed, most (64%) think it will be less than a year before people can start receiving it.

How long will take to develop a COVID-19 treatment/vaccine?

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>North America</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 6 months</td>
<td>21%</td>
<td>11%</td>
</tr>
<tr>
<td>6 months to 1 year</td>
<td>42%</td>
<td>46%</td>
</tr>
<tr>
<td>1 to 2 years</td>
<td>29%</td>
<td>37%</td>
</tr>
<tr>
<td>2 to 5 years</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>More than 5 years</td>
<td>2%</td>
<td>1%</td>
</tr>
</tbody>
</table>

n=474 | Base: All respondents excluding those who did not know

BY REGION

North Americans are more likely to think a treatment or vaccine for the virus will be developed in less than 6 months and are also more likely to think that, once developed, a new treatment or vaccine could be made available in less than 6 months compared to those from Europe.
Participation in COVID-19 Clinical Trials

Slightly more than half (55%) are willing to participate in a COVID-19 clinical research study.

Top motivators for participation mirror findings from the baseline 2019 Perceptions & Insights Study with altruistic reasons topping the list.

BY REGION
While 60% of those in Europe are ‘somewhat’ or ‘very willing,’ 48% of those in North America are willing to participate in a COVID-19 clinical research study.

BY COVID-19 SYMPTOMS, TESTING
Those who have experienced symptoms of the virus are more willing to participate in a COVID-19 clinical research study (29% “very willing”) compared to those who have never experienced COVID-19 symptoms (14% “very willing”).

Which of the following are reasons you would participate in a COVID-19 clinical research study?

- Receive free medication: 17%
- Receive money: 29%
- Obtain better treatment for COVID-19: 34%
- Help others who suffer from COVID-19: 46%
- Advance science, treatment of COVID-19: 46%

Which of the following are reasons you would not participate in a COVID-19 clinical research study?

- Risk of placebo: 12%
- Don’t know enough about research: 16%
- Don’t want to be treated like a test subject: 20%
- Risks associated with clinical studies: 30%
- Don’t want to take chance on health: 45%
## Current Clinical Trial Implications

Those enrolled in ongoing clinical trials for illnesses other than COVID-19 are being impacted by the pandemic.

### What changes have you experienced in your clinical trial as a result of the COVID-19 pandemic?

<table>
<thead>
<tr>
<th>Change</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of telemedicine</td>
<td>42%</td>
</tr>
<tr>
<td>In-person clinic visits to virtual clinic visits</td>
<td>34%</td>
</tr>
<tr>
<td>Suspension of clinical research study</td>
<td>26%</td>
</tr>
<tr>
<td>Study medication delivered directly to home</td>
<td>21%</td>
</tr>
<tr>
<td>Use of smartphone apps</td>
<td>21%</td>
</tr>
<tr>
<td>Reduced number of in-person clinic visits</td>
<td>11%</td>
</tr>
</tbody>
</table>

n=38 | Base: Those currently enrolled in a clinical trial for a medical condition other than COVID-19, who have experienced changes
ABOUT CISCRP

The Center for Information and Study on Clinical Research Participation (CISCRP) is an internationally recognized non-profit organization dedicated to educating and informing the public and patients about clinical research. CISCRP works to raise awareness, enhance experiences, and strengthen communication and relationships among participants, research professionals and the public through various services and events.

Additional Resources
Designed to help professionals best engage patients as partners in the clinical research process. www.ciscrp.org Education Center, Quarterly eNewsletter, Search Clinical Trials, Sponsorship Opportunities, Webinars, Online Store

For more information about CISCRP and our services, contact us at 877-633-4376, email info@ciscrp.org or visit www.ciscrp.org